Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer.

Autor: Sheng IY; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Barata P; Department of Internal Medicine, Section of Hematology Oncology, Tulane University Medical School, New Orleans, LA, USA., Alameddine R; Department of Hematology Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA., Garcia JA; Department of Hematology Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA.
Jazyk: angličtina
Zdroj: Drugs in context [Drugs Context] 2021 Mar 15; Vol. 10. Date of Electronic Publication: 2021 Mar 15 (Print Publication: 2021).
DOI: 10.7573/dic.2020-10-2
Abstrakt: Significant changes in the management of patients with de novo metastatic prostate cancer have led to the use of novel oral agents and docetaxel-based chemotherapy earlier in the natural history of their disease. Our main challenge is the lack of prospective randomized data comparing these regimens. It is clear that treatment intensification is needed. Yet, the heterogeneity of this patient population coupled with the lack of understanding of the specific biology for a given individual makes treatment selection challenging. The aim of this narrative review is to discuss the importance of defining advanced disease by volume, the necessity for treatment intensification, and the current and future landscape of metastatic hormone-sensitive prostate cancer management.
Competing Interests: Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/02/dic.2020-10-2-COI.pdf
(Copyright © 2021 Sheng IY, Barata P, Alameddine R, Garcia JA.)
Databáze: MEDLINE
Externí odkaz: